share_log

復星醫藥：海外監管公告 - 關於控股子公司獲藥品註冊批准的公告

FOSUN PHARMA: Overseas Regulatory Announcement - Announcement in Relation to the Approval for Drug Registration of a Subsidiary

Hong Kong Stock Exchange ·  Apr 24 18:20
Summary by Futu AI
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司沈陽紅旗製藥有限公司自主研發的新藥——環絲氨酸膠囊，已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥主要用於治療對一線抗結核藥物反應不佳的活動性肺結核和肺外結核，包括肾结核。復星醫藥預計此次新藥上市將為結核病治療提供更多選擇，並進一步豐富公司產品線，但預計不會對當前階段的業績產生重大影響。公司提醒投資者，由於醫藥產品行業的特點，新藥上市後的銷售情況存在不確定性，敬請注意投資風險。公告日期為2024年4月24日。
上海復星醫藥（集團）股份有限公司（簡稱「復星醫藥」）宣布其控股子公司沈陽紅旗製藥有限公司自主研發的新藥——環絲氨酸膠囊，已於近日獲得國家藥品監督管理局的上市註冊批准。該新藥主要用於治療對一線抗結核藥物反應不佳的活動性肺結核和肺外結核，包括肾结核。復星醫藥預計此次新藥上市將為結核病治療提供更多選擇，並進一步豐富公司產品線，但預計不會對當前階段的業績產生重大影響。公司提醒投資者，由於醫藥產品行業的特點，新藥上市後的銷售情況存在不確定性，敬請注意投資風險。公告日期為2024年4月24日。
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED THAT ITS HOLDING SUBSIDIARY SHENYANG RED FLAG PHARMACEUTICAL CO., LTD. INDEPENDENTLY DEVELOPED NEW DRUG, CYPRESSINE CAPSULES, HAS RECENTLY BEEN APPROVED FOR LISTING BY THE NATIONAL DRUG ADMINISTRATION. The new drug is primarily used to treat active TB and extrapulmonary tuberculosis, including renal tuberculosis, which respond poorly to first-line anticoagulant drugs. FUSTAR PHARMACEUTICALS EXPECTS THIS NEW DRUG LAUNCH TO PROVIDE MORE OPTIONS FOR TUBERCULOSIS TREATMENT AND FURTHER ENRICH THE COMPANY'S PRODUCT LINE, BUT IS NOT EXPECTED TO HAVE A SIGNIFICANT IMPACT ON PERFORMANCE AT THIS STAGE. THE COMPANY REMINDS INVESTORS THAT DUE TO THE CHARACTERISTICS OF THE PHARMACEUTICAL PRODUCT INDUSTRY, THERE IS UNCERTAINTY IN THE SALES SITUATION OF NEW DRUGS AFTER THE LAUNCH OF NEW DRUGS. THEY ARE MINDFUL OF INVESTMENT RISKS. The announcement date is 24 April 2024.
SHANGHAI FUSTAR PHARMACEUTICALS (GROUP) CO., LTD. (“FUSTAR PHARMACEUTICALS”) ANNOUNCED THAT ITS HOLDING SUBSIDIARY SHENYANG RED FLAG PHARMACEUTICAL CO., LTD. INDEPENDENTLY DEVELOPED NEW DRUG, CYPRESSINE CAPSULES, HAS RECENTLY BEEN APPROVED FOR LISTING BY THE NATIONAL DRUG ADMINISTRATION. The new drug is primarily used to treat active TB and extrapulmonary tuberculosis, including renal tuberculosis, which respond poorly to first-line anticoagulant drugs. FUSTAR PHARMACEUTICALS EXPECTS THIS NEW DRUG LAUNCH TO PROVIDE MORE OPTIONS FOR TUBERCULOSIS TREATMENT AND FURTHER ENRICH THE COMPANY'S PRODUCT LINE, BUT IS NOT EXPECTED TO HAVE A SIGNIFICANT IMPACT ON PERFORMANCE AT THIS STAGE. THE COMPANY REMINDS INVESTORS THAT DUE TO THE CHARACTERISTICS OF THE PHARMACEUTICAL PRODUCT INDUSTRY, THERE IS UNCERTAINTY IN THE SALES SITUATION OF NEW DRUGS AFTER THE LAUNCH OF NEW DRUGS. THEY ARE MINDFUL OF INVESTMENT RISKS. The announcement date is 24 April 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.